Effect of antiretroviral HIV therapy on hepatitis B virus replication and pathogenicity

Intervirology

Volumn 57, Issue 3-4, 2014, Pages 212-217

  Gürtler, Lutz G ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antiretroviral therapy; HIV hepatitis B virus coinfection; Pathogenesis

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR; TRANSACTIVATOR PROTEIN; VPR PROTEIN; ALPHA INTERFERON; DNA POLYMERASE; GLYCOPROTEIN GP 120; HEPATITIS B VACCINE; HEPATITIS B VIRUS X PROTEIN; HEPATITIS B(E) ANTIGEN; HOST FACTOR; INTERLEUKIN 2; INTERLEUKIN 3; LAMIVUDINE; NEF PROTEIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIVIRAL THERAPY; ARTICLE; DRUG EFFECT; ESCHERICHIA COLI; HELPER CELL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; T LYMPHOCYTE; VACCINATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS VIRULENCE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; COINFECTION; COMPLICATION; DRUG EFFECTS; HEPATITIS B, CHRONIC; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; PATHOGENICITY; VIROLOGY; AMINO ACID SEQUENCE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; APOPTOSIS; COMBINATION CHEMOTHERAPY; CYTOTOXIC T LYMPHOCYTE; ENZYME STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOPATHOLOGY; LIVER CARCINOGENESIS; LIVER CIRRHOSIS; LIVER NECROSIS; MIXED INFECTION; MONOTHERAPY; PROTEIN MOTIF; QUALITY OF LIFE; REVERSE TRANSCRIPTION; SEROCONVERSION; THERAPY EFFECT; TREATMENT OUTCOME; VIRUS MUTATION;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COINFECTION; DEOXYCYTIDINE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV SEROPOSITIVITY; HIV-1; HUMANS; INFLAMMATION; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

CERCOPITHECINE HERPESVIRUS 1; DNA VIRUSES; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84904676415     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000360942     Document Type: Article

References (30)

1. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA: Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256: 1783-1790.
2. Hu WS, Hughes SH: HIV-1 reverse transcription. Cold Spring Harb Perspect Med 2012; 2:a006882.
3. Le Grice SF: Human immunodeficiency virus reverse transcriptase: 25 years of research, drug discovery, and promise. J Biol Chem 2012; 287: 40850-40857.
4. Arts EJ, Hazuda DJ: HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2012; 2:a007161.
5. Poch O, Sauvaget I, Delarue M, Tordo N: Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 1989; 8: 3867-3874.
6. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E: Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001; 75: 4771- 4779.
7. Ghany M, Liang TJ: Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterol 2007; 132: 1574- 1585.
8. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF: Nomenclature for antiviral resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33: 751-757.
9. Levy JA: HIV and the Pathogenesis of AIDS, ed 3. Washington, ASM Press, 2007.
10. Mallet V, Vallet-Pichard A, Pol S: The impact of human immunodeficiency virus on viral hepatitis. Liver Int 2011; 31(suppl 1):135-139.
11. Herbein G, Gras G, Khan KA, Abbas W: Macrophage signaling in HIV-1 infection. Retrovirology 2010; 7: 34.
12. Azurmanyan A, Reis HMGP, Feitelson MA: Pathogenic mechanisms in HBV- and HCVassociated hepatocellular carcinoma. Nat Rev Cancer 2013; 13: 123-135.
13. Yu Y, Gong R, Mu X, Chen Y, Zhu C, Sun Z, Chen M, Lin Y, Zhu Y, Wu J: Hepatitis B virus induces a novel inflammation network involving three inflammatory factors, IL-29, IL- 8, and cycloxygenase 2. J Immunol 2011; 187: 4844-4860.
14. Foster JL, Denial SJ, Temple BR, Garcia JV: Mechanism of HIV-1 Nef function and intracellular signaling. J Neuroimmune Pharmacol 2011; 6: 230-246.
15. Ptak RG, Fu W, Sanders-Beer BE, Dickerson JE, Pinney JW, Robertson DL, Rozanov MN, Katz KS, Maglott DR, Pruitt KD, Dieffenbach CW: Cataloguing the HIV type 1 human protein interaction network. AIDS Res Hum Retroviruses 2008; 24: 1497-1502.
16. Rehermann B: Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013; 19: 859-868.
17. Chang J, Block TM, Guo JT: The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. Antiviral Res 2012; 96: 405-413.
18. Mu Y, Yu Y, Yue X, Musarat I, Gong R, Zhu C, Liu Y, Liu F, Zhu Y, Wu J: The x protein of HBV induces HIV-1 long terminal repeat transcription by enhancing the binding of C/ EBP and CREB1/2 regulatory proteins to the long terminal repeat of HIV-1. Virus Res 2011; 156: 81-90.
19. Li YJ, Wang HL, Li TS: Hepatitis B virus/human immunodeficiency virus coinfection: interaction among human immunodeficiency virus infection, chronic hepatitis B infection, and host immunity. Chin Med J 2012; 125: 2371-2377.
20. Zoutendijk R, Zaajer HL, de Vries-Sluijs TEMS, Reijnders JGP, Mulder JW, Kroon FP, Richter C, van der Eijk AA, Sonneveld MJ, Hansen BE, de Man RA, van der Ende ME, Janssen HLA: Hepatitis B surface antigen decline and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV. J Infect Dis 2012; 206: 974-980.
21. Klein MB, Baril JG, Charron MA, Fortin C, Lalonde R, Matte MF, Poliquin M, Talbot A, Therrien R, Tremblay C, Troittier B, Tsarevsky I, Villeneuve JP: Management and treatment of hepatitis B virus in patients with HIV infection: a practical guide for health care professionals: Can J Infect Dis Med Microbiol 2011; 22: 88-96.
22. Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, Kuzushita N, Mauss S, Nuez M, Nuesch R, Peters M, Reiberger T, Stephan C, Tan L, Gilson R: Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS One 2013; 8:e68152.
23. Lada O, Gervais A, Branger M, Peytavin G, Roquebert B, Collin G, Fraquiero G, Moucari R, Hamet G, Martinot-Peignoux M, Matheron S, Marcellin P: Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G. Liver Int 2012; 32: 93-101.
24. Laprise C, Baril JG, Dufresne S, Trottier H: Association between tenofovir exposure and reduced kidney function in a cohort of HIV positive patients: results from 10 years of follow- up. Clin Infect Dis 2013; 56: 567-575.
25. Anderson AM, Mosunjac MB, Palmore MP, Osborn MK, Muir AJ: Development of fatal acute liver failure in HIV-HBV coinfected patients. World J Gastroenterol 2010; 16: 4107- 4111.
26. Chun HM, Roediger MP, Hullsiek KH, Thio CL, Agan BK, Bradley WP, Peel SA, Jagodzinski LL, Weintrob AC, Ganesan A, Wortmann G, Crum-Cianflone NF, Maguire JD, Landrum ML: Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis 2012; 205: 185-193.
27. Seeger C, Mason WS: Sodium-dependent taurocholic cotransporting polypeptide: a candidate receptor for human hepatitis B virus. Gut 2013; 62: 1093-1095.
28. Shugarts S, Benet LZ: The role of transporters in the pharmacokinetics of orally administered drugs. Pharmaceut Res 2009; 26: 2039- 2054.
29. Kosi L, Reiberger T, Payer BA, Grabmeier- Pfistershammer K, Strassl R, Rieger A, Peck- Radosavljevic M: Five-year on-treatment efficacy of lamivudine-tenofovir and tenofovir + emtricitabine-based HAART in HBV-HIVcoinfected patients. J Viral Hepat 2012; 19: 801-810.
30. Wang S, Chen Z, Hu C, Qian F, Cheng Y, Wu M, Shi B, Chen J, Hu Y, Yuan Z: Hepatitis B surface antigen selectively inhibits TLR2 ligand- induced IL-12 production in monocytes/ macrophages by interfering with JNK activation. J Immunol 2013; 190: 5142-5151.